C4 Therapeutics, Inc. (CCCC): R&D Expense
$104.24M
Year ended 2025-12-31
$100.05M
Trailing 12 months to 2026-06-30
-4.0%
3-year compound annual growth
+5.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $104.24M | -5.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $110.64M | -6.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $117.71M | -0.1% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $117.84M | +24.5% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $94.67M | +20.7% | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | $78.44M | +63.2% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $48.06M | n/a | 2022-02-24, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $316.57M | +31.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $250.0K | -18.6% |
Compare CCCC, XFOR, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗